Citation:
Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, ……… Marsh J, McGlothlin A, et al. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022;75(11):2027-34.
Keywords:
Staphylococcus aureus; adaptive platform; bacteremia; bloodstream infection; randomized controlled trial; antiinfective agent; Staphylococcus infection; anti-Bacterial Agents
Abstract:
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection.